



Published in final edited form as:

*Ann Neurol.* 2019 April ; 85(4): 538–549. doi:10.1002/ana.25430.

## Cholinergic system changes of falls and freezing of gait in Parkinson disease

Nicolaas I. Bohnen, MD, PhD<sup>1,2,3,4</sup>, Prabesh Kanel, PhD<sup>1,4</sup>, Zhi Zhou, MD<sup>1</sup>, Robert A. Koeppe, PhD<sup>1,4</sup>, Kirk A. Frey<sup>1,2</sup>, William T. Dauer, MD<sup>2,3,4</sup>, Roger L. Albin, MD<sup>2,3,4</sup>, and Martijn L.T.M. Müller, PhD<sup>1,4</sup>

<sup>1</sup>Radiology, University of Michigan, Ann Arbor, MI, United States, 48104;

<sup>2</sup>Neurology, University of Michigan, Ann Arbor, MI, United States, 48104;

<sup>3</sup>Neurology Service and GRECC, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, MI, United States, 48104;

<sup>4</sup>Morris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI, United States.

### Abstract

**Objective:** Postural instability and gait difficulties (PIGD) represent debilitating disturbances in Parkinson's disease (PD). Prior acetylcholinesterase PET imaging studies implicate cholinergic changes as significant contributors to PIGD features. These studies were limited in quantification of striatal cholinergic synapse integrity. Vesicular acetylcholine transporter (VACHT) PET ligands are better suited for evaluation of high binding areas. We examined associations between regional VACHT expression and freezing of gait (FoG) and falls.

**Methods:** Ninety-four PD subjects underwent clinical assessment and VACHT (<sup>18</sup>F]FEOBV) PET.

**Results:** Thirty-five subjects (37.2%) reported a history of falls and 15 (16%) had observed FoG. Univariate volume-of-interest analyses demonstrated significantly reduced thalamic (P=0.0016) VACHT expression in fallers compared to non-fallers. VACHT expression was significantly reduced in the striatum (P=0.0012) and limbic archicortex (P=0.004) in freezers compared to non-freezers. Whole brain voxel-based analyses of FEOBV PET complemented these findings and showed more granular changes associated with falling history including the right visual thalamus (especially the right lateral geniculate nucleus, LGN), right caudate nucleus, and bilateral prefrontal regions. Freezers had prominent VACHT expression reductions in the bilateral striatum, temporal and mesiofrontal limbic regions.

---

Corresponding author: Nicolaas Bohnen, Functional Neuroimaging, Cognitive and Mobility Laboratory, Departments of Radiology and Neurology, University of Michigan, 24 Frank Lloyd Wright Drive, Box 362, Ann Arbor, MI 48105-9755, TEL: (1) 734 936 5388; FAX: (1) 734 998 8403. nbohen@umich.edu.

Author contributions

NB, MM designed the study, NB, MM, RLA, RK, PK, ZZ and RAK acquired and/or analyzed the data. NB, RA and MM drafted the manuscript, which was reviewed and revised by all coauthors.

Potential conflicts of interests

Nothing to report.

**Interpretation:** Our findings confirm and extend on previous PET findings of thalamic cholinergic deficits associated with falling history and now emphasize right visual thalamus complex changes, including the right LGN. FoG status is associated with reduced VAcHT expression in striatal cholinergic interneurons and the limbic archicortex. These observations suggest different cholinergic systems changes underlying falls and FOG in PD.

### Keywords

Acetylcholine; caudate nucleus; falls; freezing of gait; lateral geniculate nucleus; Parkinson disease; PET; thalamus

---

### Introduction

Advancing Parkinson disease (PD) is associated with debilitating postural instability and gait difficulties (PIGD), such as falls and freezing of gait (FoG)<sup>1</sup>. The Sydney Multicenter Study of PD found that dopamine non-responsive PIGD dominate motor function 15 years after initial assessments and includes frequent falls, occurring in 81% of subjects<sup>2</sup>. Another incident cohort reported that 68% of PD subjects exhibited postural instability at 10-year follow-up<sup>3</sup>. Dopaminergic medication ‘on’ freezing has been reported in 38% of a large series of subjects with PD<sup>4</sup>.

Absent dopaminergic therapy responses implicates non-dopaminergic mechanisms in worsening PIGD motor features. Major populations of central nervous system cholinergic neurons include the basal forebrain (BF) complex, the brainstem pedunculopontine nucleus/lateral dorsal tegmental complex (PPN/LTDC), and striatal cholinergic interneurons. We previously associated PPN/LTDC-thalamic and BF corticopetal cholinergic projection system degeneration with falls and slow gait speed in PD, respectively<sup>5, 6</sup>. Using dopaminergic, acetylcholinesterase (AChE) and  $\beta$ -amyloid PET imaging, we also reported reduced striatal dopaminergic terminals, reduced diffuse cortical cholinergic terminals, and more severe cortical amyloidopathy in PD freezers compared to non-freezers<sup>7</sup>.

Our previous AChE PET imaging studies were limited due to the ligand’s inability to reliably estimate tracer hydrolysis rates in high binding areas, such as the striatum or cerebellum<sup>8</sup>. This limits identification of potentially relevant fall or FoG associated markers<sup>9</sup>. [<sup>18</sup>F]-fluoroethoxybenzovesamicol ([<sup>18</sup>F]-FEOBV) is a PET radioligand that selectively binds to the vesicular acetylcholine transporter (VAcHT)<sup>10</sup>. An advantage of [<sup>18</sup>F]-FEOBV PET is that ligand binding in regions with high cholinergic terminal density can be more accurately estimated<sup>11</sup>.

The objective of this study is a detailed *in vivo* examination of regional cerebral, including cortical and subcortical, VAcHT expression in PD subjects with PIGD motor features. We hypothesized that distinct distributed patterns of subcortical and cortical cholinergic projection system changes are associated with FoG and falls in PD. Based on our prior AChE studies, we hypothesized a central role for thalamic involvement for falls and cortical changes underlying FoG.

## Methods

### Subjects and clinical test battery

This study involved 94 subjects with PD (72 males; 22 females), mean age  $67.9 \pm 7.6$  (SD; range 51–93) years. PD subjects met the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria<sup>12</sup>. Subjects with evidence of large vessel stroke or other intracranial lesions on anatomic imaging were excluded. The movement disorder society-revised unified PD rating scale (MDS-UPDRS) motor examination was performed in the morning in the dopaminergic medication 'off' state.

Subjects completed the Montreal Cognitive Assessment with mean score of  $26.2 \pm 3.3$  (range 10–30)<sup>13</sup>. Mean duration of disease was  $6.0 \pm 4.5$  (range 1–30) years. The mean motor examination score on the MDS-UPDRS was  $33.9 \pm 13.8$  (range 2–74)<sup>14</sup>.

Thirty-one PD subjects were taking a combination of dopamine agonist and carbidopa-levodopa medications, 47 were using carbidopa-levodopa alone, 10 were taking dopamine agonists alone and 6 were not receiving dopaminergic drugs. Mean levodopa equivalent dose (LED) was  $655.5 \pm 397.8$  (range 0–1,902.5) mg<sup>15</sup>. No subjects were treated with anti-cholinergic or cholinesterase inhibitor drugs. Most subjects had moderate severity of disease: 6 subjects in stage 1, 3 in stage 1.5, 20 in stage 2, 40 in stage 2.5, 20 in stage 3, 5 in stage 4 of the modified Hoehn and Yahr classification with mean stage of  $2.45 \pm 0.6$ .

### Fall and FoG assessment

Participants were asked about a history of falling. A fall was defined as an unexpected event during which a person falls to the ground. The presence or absence of FoG was based on clinical examination and directly observed by the clinician examiner based on a non-zero score on item 3.11 'Freezing of Gait' of the MDS-UPDRS motor examination<sup>14</sup>. For most reliable assessment, FoG classification should be based upon objective confirmation by an experienced observer during clinical assessment rather than on patient recollection<sup>16</sup>. This study was approved by the Institutional Review Boards of the University of Michigan School of Medicine and Veterans Affairs Ann Arbor Healthcare System. Written informed consent was obtained from all subjects.

### Imaging techniques

Magnetic resonance imaging (MRI) was performed on a 3 Tesla Philips Achieva system (Philips, Best, The Netherlands). A 3D inversion recovery-prepared turbo-field-echo was performed in the sagittal plane using TR/TE/TI=9.8/4.6/1041ms; turbo factor=200; single average; FOV=240×200×160mm; acquired Matrix = 240×200×160 slices and reconstructed to 1mm isotropic resolution.

PET imaging was performed in 3D imaging mode with a Siemens ECAT Exact HR+ tomograph or Biograph 6 TruPoint PET/CT scanner (Siemens Molecular Imaging, Inc., Knoxville, TN), which acquire 63 transaxial slices (slice thickness: 2.4 mm) over a 15.2 cm axial field-of-view. Images were corrected for scatter and motion. Subjects were scanned in the dopaminergic medication 'on' state.

[<sup>18</sup>F]FEOBV was prepared as described previously<sup>17, 18</sup>. [<sup>18</sup>F]-FEOBV delayed dynamic imaging was performed over 30 minutes (in six 5-minute frames) starting 3 hours after an intravenous bolus dose injection of 8 mCi [<sup>18</sup>F]-FEOBV<sup>11</sup>. The PET imaging frames were spatially coregistered within subjects with a rigid-body transformation to reduce the effects of subject motion during the imaging session<sup>19</sup>. Statistical parametric mapping (SPM) software (SPM12; Wellcome Trust Centre for Neuroimaging, University College, London, England [<https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>]) was used for PET-MRI registration using the cropped T1-weighted MR volumetric scan. Freesurfer software (<http://surfer.nmr.mgh.harvard.edu>) was used to define cortical and subcortical MR gray volumes-of-interest (VOI).

A white matter reference tissue approach was used to determine VAcH binding as previously reported<sup>20, 21</sup>. This approach departs from previously used cerebellar gray matter reference regions<sup>11</sup>. This is appropriate as cholinergic terminal changes may occur in cerebellar cortices in parkinsonian disorders<sup>22</sup>, which may potentially bias findings using this reference region in these particular patient populations. Distribution volume ratios (DVR) were calculated from ratio of summed six delayed imaging frames (3 hours after injection) for gray matter target and white matter reference tissues<sup>21</sup>.

### Volume-of-interest and voxel-based brain PET analysis

VOI and voxel-based methods provide complementary information. The following bilaterally averaged VOIs were defined for the striatum (putamen and caudate nucleus), thalamus, cerebellar gray matter, brainstem, limbic archicortex (hippocampus and amygdala), and neocortex based on combination of individual labels from the Mindboggle-101 dataset segmented in FreeSurfer.

Complementary whole-brain voxel-based [<sup>18</sup>F]FEOBV PET analyses were performed to explore more granular regional brain VAcH binding changes that may not be captured or missed by pre-defined VOIs. Voxel-based statistical analysis was performed using SPM12 software on the parametric [<sup>18</sup>F]FEOBV DVR images of all subjects. For SPM analysis, all brain images were spatially normalized to Montreal Neurological Institute (MNI) template space using DARTEL normalization protocol and smoothed with a Gaussian kernel of 4 mm full width half maximum to adjust the anatomical variability between the individual brains and to enhance the signal-to-noise ratio.

### Statistical analysis

Standard pooled-variance *t*-test or approximate *t*-tests based on rank normalization were used for statistical group comparisons (SAS version 9.3, SAS institute, Cary, North Carolina). Stepwise logistic regression was performed using fall or FoG status as the outcome parameter, and VOI-based regional VAcH binding as PET regressors. Analyses were performed using SAS version 9.3, SAS institute. Statistical inferences were made on meeting two-tailed testing requirement for  $\alpha < 0.05$  and Holm-Bonferroni correction for multiple testing for all clinical group comparisons and brain PET VOI analyses.

To complement the VOI based analyses we performed two main exploratory whole brain voxel-wise analyses to compare the total group of fallers *versus* non-fallers and total group

of freezers *versus* non-freezers, respectively. For this purpose, we designed a two-sample voxel-based *t*-test for to compare different groups. We thresholded statistical parametric maps at  $P=0.0125$  with minimum cluster size of 50 voxels. We then identified clusters of significant voxels in anatomic sub-regions that were consistent with our hypotheses and/or concordant with regional cerebral results demonstrated by these VOI analyses. Statistically significant clusters, corrected for multiple comparisons using family-wise error (FWE), were identified using the small volume (radius of VOI at 5mm) voxel-based method as previously reported<sup>23</sup>.

Finally, we performed *post hoc* exploratory analyses to further evaluate any regional brain findings of these main voxel-based analyses by comparing sub-sets of patients of various combinations of fall and FoG status for more pure mechanistic analyses underlying fall and FoG status, respectively. As some of the regional brain locomotor or motor control region may represent anatomically small structures (*i.e.*, clusters smaller than 50 voxels) we did not filter out the parametric images for a minimal cluster size. Significant clusters were also identified by the small volume FWE correction method<sup>23</sup>.

## Results

### Clinical findings: falls and freezing status

Thirty-five subjects (37.2%) reported a history of falls. Fallers had longer duration of disease, greater motor disease severity, higher Hoehn & Yahr scores, higher LED, higher frequency of reporting acting out of dreams and worse cognitive performance than non-fallers; however, there were no significant differences in gender distribution or age (Table 1).

FoG was present in 15 subjects (16.0%). Freezers were older, had longer duration of disease, higher mean Hoehn & Yahr score, more severe motor disease, higher LED, and worse cognitive performance than non-freezers (Table 2). There were no significant differences in gender distribution or frequency of reporting acting out of dreams between groups.

### Regional cerebral FEOBV VOI PET findings in fallers

Univariate VOI analyses (corrected for multiple testing) demonstrated significantly reduced thalamic ( $P=0.0016$ ) VAcHT expression in fallers compared to non-fallers (table 3). None of the other regions retained significance after correction for multiple testing. In a *post hoc* analysis we explored whether this finding was lateralized and entered the left and right thalamic VOIs in a backward stepwise logistic regression analysis yielding right thalamic VAcHT binding as the single regressor meeting the model's entry criteria (Wald  $\chi^2=9.1$ ,  $p=0.0025$ ).

### Regional cerebral FEOBV VOI PET findings in freezers

Univariate VOI analysis showed reduced striatal and limbic archicortical VAcHT binding in freezers compared to non-freezers (table 4). These two regions were entered in backward stepwise logistic regression analysis yielding striatal VAcHT binding as the single regressor meeting the model's entry criteria (Wald  $\chi^2=8.6$ ,  $p=0.0034$ ). In a *post hoc* analysis we explored whether this involved the lateralized caudate nucleus *versus* the lateralized

putamen. The left and right putamina and caudate nuclei VACHT VOIs were entered in backward stepwise logistic regression analysis yielding the right caudate nucleus VACHT binding as the single regressor meeting the model's entry criteria (Wald  $\chi^2 = 9.3$ ,  $p = 0.0023$ ).

### Post hoc confounder variable analysis

A *post hoc* analysis of covariance (ANCOVA) was performed to determine possible confounder effects of significant clinical variables (LED, MOCA score and duration of disease) where LED and duration of disease are proxy variables for overall disease severity. The total model for fall status was significant ( $F_{(4,89)} = 3.53$ ,  $P = 0.01$ ) with significant effects for thalamic VACHT binding ( $F = 6.17$ ,  $P = 0.015$ ), borderline for MOCA scores ( $F = 3.30$ ,  $P = 0.072$ ) but not significant for duration of disease or LED. Similar ANCOVA for FoG status demonstrated a significant overall model ( $F_{(4,89)} = 3.26$ ,  $P = 0.015$ ) with significant effect for striatal VACHT binding ( $F = 8.14$ ,  $P = 0.0054$ ) but no significant covariate effects for duration of disease, MOCA or LED.

### Voxel-based whole brain FEOBV PET analyses

Whole brain voxel-based analyses were performed to compare the total of 35 fallers to 59 non-fallers (analysis 1) and a total of 15 subjects with FoG compared to 79 non-freezers (analysis 2).

### Main whole brain voxel-based analysis 1: PD fallers versus non-fallers (all fallers)

Significant FEOBV binding reductions (FWE-corrected  $P$  values ranging from 0.032 to 0.040) were found in the total group of PD fallers ( $n=35$ ) versus non-fallers ( $n=59$ ) in the dorsomedial thalamus (right greater than left), right lateral geniculate nucleus (LGN), right pulvinar, right head of the caudate nucleus, pre-frontal, right temporopolar, right mesiotemporal, right more than left insula, superior vermis and bilateral superior cerebellar peduncle regions (Figure 1). Additional FEOBV binding reductions were present in the anterior cingulate cortex. There were no areas of significantly increased FEOBV binding in fallers compared to non-fallers.

### Main whole brain voxel-based analysis 2: PD freezers versus non-freezers (all freezers)

Whole brain voxel-based analysis comparing the freezers ( $n=15$ ) to the non-freezers ( $n=79$ ) demonstrating significant FEOBV binding reductions (FWE-corrected  $P$  values ranging from 0.034 to 0.041) in the left hippocampal region, bilateral prefrontal and bilateral anterior cinguli (Figure 2). Additional reductions were seen in the striatum, including right more than left caudate and accumbens nuclei and putamina, bilateral limbic archicortex, bilateral gyri recti, right LGN, and right mid-cingulate cortex regions (Figure 2).

### Post hoc exploratory voxel-based analysis of specific sub-sets of variable combinations of fall and FoG status

Finally, we compared sub-sets of subjects with variable combination of falls and/or FoG status to allow a more 'pure' mechanistic assessment of intrinsic fall and FoG phenomena. The first *post hoc* analysis compared PD fallers without FoG ( $n=24$ ) versus PD non-fallers

without FoG (n=55) for more ‘pure’ assessment of fall patterns. The second *post hoc* analysis compared fallers with FoG (n=11) to fallers without FoG (n=24) to better capture the intrinsic pattern changes associated with ‘pure’ freezing motor behaviors.

### **Post hoc exploratory voxel-based analysis 1: PD fallers without FoG versus PD non-fallers without FoG (‘pure’ falls)**

We compared the number of PD fallers without FoG to PD non-fallers also without FoG to explore a more neurobiological pattern of intrinsic fall mechanisms. Significant (FWE-corrected P values ranging from 0.033 to 0.046) clusters included the right LGN, right caudate nucleus, right premotor cortex, right lateral temporal, right frontal eye field, right temporopolar cortex, right posterior cingulum, right proximal lingual gyrus, and bilateral prefrontal regions (Figure 3). Additional reductions were seen in the right more than left sensorimotor cortices.

### **Post hoc exploratory voxel-based analysis 2: PD fallers with FoG versus PD fallers without FoG (‘pure’ FoG)**

We also compared fallers with FoG to fallers without FoG to better capture the intrinsic changes underlying freezing motor behaviors and found significant clusters of reduced VAcHT binding (FWE-corrected P levels ranging from 0.034 to 0.046) in the left hippocampus, right temporal lobe, anterior cingulum, and cerebellum (Figure 4). Additional reductions were seen in the bilateral basal ganglia, limbic archicortex, right LGN and right insula.

Finally, a *post hoc* confounder analysis to determine any possible effect of LED medication effects on the regional cholinergic binding did not significantly change the main findings.

## **Discussion**

Although falls and FoG are interconnected episodic phenomena<sup>1</sup>, our findings show that these represent partially distinct entities with probable differing pathophysiology. VOI-based analysis identified the thalamus and striatum as critical regions contributing to falls and FoG in PD, respectively. Thalamic cholinergic deficits, for example, are associated with impaired postural reflexes, whose underlying pathophysiology may differ from that leading to FoG<sup>24, 25</sup>. We found that history of falls is associated with cholinergic projection system changes in which the thalamus is likely a key node while FoG is associated with changes for which the caudate nucleus is likely a key node.

[<sup>18</sup>F]FEOBV is a specific VAcHT ligand and marker of cholinergic terminals.<sup>10</sup> The regional distribution of [<sup>18</sup>F]FEOBV binding in human brain is identical to the distribution of cholinergic terminals described in post-mortem human brain studies<sup>26</sup>. The diminished [<sup>18</sup>F]FEOBV binding we describe in brain regions of PD falling and/or freezing subjects compared to those without these PIGD features is most compatible with degeneration (or greater degeneration) of cholinergic terminals. This inference is consistent with preclinical studies demonstrating that lesions of the BF complex or PPN result in significantly diminished [<sup>18</sup>F]FEOBV binding in target regions of these projections<sup>27, 28</sup>. Similarly, Schmitz et al. demonstrated a good correlation between cortical [<sup>18</sup>F]FEOBV binding

deficits and basal forebrain nuclei atrophy in subjects with probable early Alzheimer disease<sup>29</sup>. Another important point for interpreting our results is that while basal forebrain projections to neocortex were conceived historically as a diffuse projection system, recent data indicate that subpopulations of BF cholinergic neurons project to relatively restricted cortical regions<sup>30</sup>. The VOI and VB cortical [<sup>18</sup>F]FEOBV binding reductions we describe likely reflect degeneration or dysfunction of subpopulations of BF cholinergic neurons. Diminished [<sup>18</sup>F]FEOBV binding in the amygdala and hippocampal formation of PD subjects with FoG likely reflects disproportionate degeneration of more rostral BF cholinergic projection neurons. Similarly, diminished frontal cortical [<sup>18</sup>F]FEOBV binding in PD subjects with history of falls likely reflects preferential loss of subpopulations of more caudal BF cholinergic projection neurons.

Falling is a serious axial motor impairment in PD. There is converging evidence that cholinergic input from the PPN/Laterodorsal tegmental complex (LDTc) to the thalamus may play an important role in the pathophysiology of falls in PD<sup>5, 7, 24, 25</sup>. Our present study, using a more specific PET cholinergic terminal ligand and a different population of subjects, confirms our previous AChE PET imaging findings that PD fallers have lower density of thalamic cholinergic nerve terminals compared to non-fallers<sup>5</sup>. This inference is consistent with a *post mortem* study that found evidence of lower PPN cholinergic neuron counts in PD subjects with falls during life compared to non-fallers<sup>24</sup>. While the human thalamus also receives cholinergic inputs from the BF complex, these are sparser than PPN/LDTc afferents and it is likely that the considerable majority of thalamic terminals arise in the PPN/LDTc complex<sup>31</sup>. This is particularly true for visual thalamic nuclei such as the pulvinar and LGN, which contain only sparse BF terminals<sup>31</sup>. Although cholinergic thalamic afferents likely play a critical role in the pathophysiology of falls in PD, PPN/LTDC-thalamic cholinergic degeneration typically occurs in the setting of BF losses<sup>32</sup>, suggesting that extensive brain cholinergic projection system deficits are also implicated in falls in PD.

Our *post hoc* VOI analysis identified the right thalamus as the most significant hypo-cholinergic brain region associated with falls. A significant limitation of the VOI-based approach, however, is that anatomic resolution is limited to pre-defined VOIs and/or Freesurfer parcellation. This particularly limits the analysis of the thalamus, where no validated nuclear parcellation is available at the present time. Complex phenomena like falls and FoG likely reflect circuit-level alterations while the VOI-based analyses identify critical nodes, it may underestimate the extent of circuit level changes. To explore circuit level alterations, we supplemented the VOI analysis with a voxel-based analysis. The voxel-based analysis suggests a more specific role of the right visual thalamus, including the pulvinar and LGN, in the pathophysiology of falls in PD. Most models of vision treat the LGN as a passive relay station to the primary visual cortex. Accumulating data, however, indicates that the pulvinar and LGN are important nodes in corticothalamocortical circuits modulating attentional function and the coordination of cortical regions for attending to stimuli and tasks<sup>33</sup>.

We can only speculate as to why we find asymmetric abnormalities in the visual thalamus (fallers) and caudate (freezers). The ventral attention network, which responds to unexpected stimuli and is highly integrated with the visual system, lateralizes to the non-dominant



hemisphere<sup>34</sup>. Hypothetically, lateralization of unique brain function(s) may require higher ipsilateral neural network or neuronal metabolic demands; which may in turn increase vulnerability to early degeneration.

These observations suggest that impaired processing of visual information relevant for safe ambulation may be compromised in PD fallers. It is conceivable that vulnerability of the right visual thalamus complex may be related to previous observations of a subtle left hemi-neglect in PD consisting of a directional (right hemi-field) bias of initial visual exploration<sup>35</sup>. Relative deficiency of detecting salient environmental visual cues from the left hemi-field may be a potential mechanism to explain increased fall risk with right LGN dysfunction. There is also evidence of perceptual asymmetry in perceptuomotor tasks without visual input. An upper body truncal rotation experiment showed evidence of contraction of left external hemispace relative to the right hemispace, possibly affecting generation and execution of motor commands through disease progression in PD<sup>36</sup>.

The voxel-based analysis implicates other brain regions as important contributors to the etiology of falls, notably the frontal cortex. Reduced cortical cholinergic signaling likely results in decreased transfer of cortical sensory and movement cues to subcortical structures such as the striatum, degrading sensorimotor integration<sup>37</sup>. Similarly, altered neocortical regulation of movement may underlie some forms of FoG<sup>38</sup>. FoG is a debilitating feature of PD that becomes more frequent with advancing disease. The magnitude of nigrostriatal dopaminergic denervation is an important pathophysiological element of FoG<sup>39</sup>. Our study confirms that the presence of FoG is related to longer duration of disease, more severe parkinsonian motor ratings, and higher LED levels. Striatal dopamine deficits, however, are likely not the only factor in FoG. First, our confounder covariate analysis did not show a significant covariate effect for LED. Second, the presence of FoG and its degree of responsiveness to dopaminergic medications correlates with exposure to anticholinergic drugs<sup>4</sup>. Freezing in PD may result from striatal dopamine loss and cortical cholinergic deafferentation, yielding striatal circuitry that lacks information about the efficacy of gait, posture, and movement and that is impaired in selecting and sequencing motor actions, resulting in slow and reluctant movements or fails to initiate movement altogether<sup>37</sup>.

Prior imaging studies found evidence of disruption of cortical function in FoG, including regions or networks involved in executive functions and sensorimotor perception in PD<sup>38, 40–42</sup>. For example, a resting state fMRI brain connectivity study identified reduced connectivity in right cortical fronto-parietal “executive-attention” and right occipitotemporal “visual” networks in PD with FOG suggesting a role of network connectivity disruption<sup>41</sup>. A diffusion tensor MRI study showed evidence of reduced connectivity between connectivity of the PPN with the cerebellum, thalamus and multiple regions of the frontal cortex<sup>43</sup>. Moreover, these structural differences were observed solely in the right hemisphere of patients with freezing of gait.

Our voxel-based analysis suggests specific roles of striatal cholinergic interneurons, especially of the right caudate nucleus, and limbic archicortical structures in FoG. Unlike the predominant motor connections of the putamen, the caudate nucleus is a node in more cognitive and affective circuits<sup>44</sup>. FoG is notably exacerbated by anxiety and often arises in

situations where there are competing cognitive demands. These observations suggest that non-motor (cognitive, affective, emotional) functions of the caudate nucleus are relevant for FoG. Degeneration or dysfunction of caudate cholinergic interneurons may disrupt corticostriatal information flow underlying the integration of goal directed behavior and sensorimotor integration and is a plausible substrate for altered network behavior underlying FoG<sup>45</sup>.

Dysfunctional limbic circuitry may underlie freezing of gait in PD. A recent resting state brain MRI found abnormal connectivity between the right amygdala and striatum in freezers compared to non-freezers<sup>46</sup>. Hippocampal abnormalities may point to altered spatial sensorimotor integration functions. FoG is notoriously associated with anxiety and the amygdalar cholinergic abnormalities we detected suggest a concrete substrate for anxiety as a determinant of FoG in PD<sup>47</sup>.

REM sleep without atonia may be a comorbid feature of patients with PD exhibiting FoG<sup>48</sup>. We previously reported reduced limbic, cortical and brainstem-thalamic acetylcholinesterase hydrolysis rates in PD patients with REM sleep behavior, suggesting partially shared cholinergic pathophysiology of these two phenomena<sup>49</sup>. We did not find a significant difference in the frequency of dream enactment behaviors in the freezers *versus* non-freezers. Our sample size, however, was small. We found an unexpected significant difference in reporting of dream enactment behavior in the fallers compared to the non-fallers. As isolated falls typically precede freezing motor behaviors during the natural course of the disease in PD<sup>50</sup>, it is possible that brainstem-thalamic cholinergic changes may be a greater determinant of this parasomnia than more anterior striatal or limbic changes. Further research is needed to explore this hypothesis.

A limitation of our study is that assessment of FoG was not based on special maneuver to identify specific sub-types of freezing motor behaviors, like making turns or passing through narrow doorways. The absence of a specific provocative FoG assessment protocol may also explain the relatively low frequency of freezing behaviors in our study sample. Consequently, this may result in a relative underestimation of effect size estimates of our study. However, our assessment protocol of direct observation of freezing behavior will result in a very high specificity of FoG classification.

In this study, we found that differential degeneration of cholinergic projections play distinct roles in postural and gait disturbances of PD. Our VOI analysis findings independently confirm previous observations that impaired integrity of thalamic cholinergic nerve terminals contributes to the pathophysiology of falls in PD. Our voxel-based analysis suggests that visual thalamus, in particular the right LGN, is a key node in disturbed circuit function underlying falls. FoG may be the result of striatal cholinergic interneurons and limbic cholinergic nerve terminals, with the right caudate nucleus as a key node in disturbed control of gait.

## Acknowledgements

The authors thank Christine Minderovic, Cyrus Sarosh, Virginia Rogers, the PET technologists, cyclotron operators, and chemists, for their assistance. We are indebted to the subjects who participated in this study.

Study funded by National Institutes of Health (P01 NS015655, RO1 NS070856, P50 NS091856), Department of Veterans Affairs grant (I01 RX001631), and the Michael J. Fox Foundation.

## Abbreviations:

<b>AChE</b>	acetylcholinesterase
<b>BF</b>	basal forebrain
<b>FEOBV</b>	[ <sup>18</sup> F]-fluoroethoxybenzovesamicol
<b>LED</b>	Levodopa Equivalent Dose
<b>LGN</b>	lateral geniculate nucleus
<b>PD</b>	Parkinson disease
<b>PIGD</b>	Postural instability and gait difficulties
<b>PPN/LDTC</b>	pedunculopontine nucleus/lateral dorsal tegmental complex
<b>VAcHT</b>	vesicular acetylcholine transporter


## References

1. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. *Movement disorders: official journal of the Movement Disorder Society*. 2004 8;19(8):871–84. [PubMed: 15300651]
2. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. *Movement disorders: official journal of the Movement Disorder Society*. 2005 2;20(2):190–9. [PubMed: 15551331]
3. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. *J Neurol Neurosurg Psychiatry*. 2013 11;84(11):1258–64. [PubMed: 23781007]
4. Perez-Lloret S, Negre-Pages L, Damier P, et al. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. *JAMA Neurol*. 2014 7 1;71(7):884–90. [PubMed: 24839938]
5. Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. *Neurology*. 2009 11 17;73(20):1670–6. [PubMed: 19917989]
6. Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. *Neurology*. 2013 9 27;81(18):1611–6. [PubMed: 24078735]
7. Bohnen NI, Frey KA, Studenski S, et al. Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study. *Movement disorders: official journal of the Movement Disorder Society*. 2014 8;29(9):1118–24. [PubMed: 24909584]
8. Koeppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE. Kinetic modeling of N-[<sup>11</sup>C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain. *J Cereb Blood Flow Metab*. 1999;19:1150–63. [PubMed: 10532640]
9. Marcone A, Garibotto V, Moresco RM, et al. [<sup>11</sup>C]-MP4A PET cholinergic measurements in amnesic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. *J Alzheimers Dis*. 2012;31(2):387–99. [PubMed: 22596267]


10. Kilbourn MR, Hockley B, Lee L, et al. Positron emission tomography imaging of (2R,3R)-5-[(18F)]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. *Nucl Med Biol.* 2009 7;36(5):489–93. [PubMed: 19520289]
11. Petrou M, Frey KA, Kilbourn MR, et al. In vivo imaging of human cholinergic nerve terminals with (-)-5-<sup>18</sup>F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. *Journal of nuclear medicine: official publication, Society of Nuclear Medicine.* 2014 3;55(3):396–404.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry.* 1992 3;55(3):181–4. [PubMed: 1564476]
13. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* 2005 4;53(4):695–9. [PubMed: 15817019]
14. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. *Movement disorders: official journal of the Movement Disorder Society.* 2007 11 17;22:41–7. [PubMed: 17115387]
15. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society.* 2010 11 15;25(15):2649–53. [PubMed: 21069833]
16. Snijders AH, Haaxma CA, Hagen YJ, Munneke M, Bloem BR. Freezer or non-freezer: clinical assessment of freezing of gait. *Parkinsonism Relat Disord.* 2012 2;18(2):149–54. [PubMed: 21968033]
17. Shao X, Hoareau R, Runkle AC, et al. Highlighting the Versatility of the Tracerlab Synthesis Modules. Part 2: Fully Automated Production of [<sup>11</sup>C]Labelled Radiopharmaceuticals using a Tracerlab FX<sub>C-PRO</sub>. *J Labelled Comp Radiopharm.* 2011 5 30;54:819–38.
18. Shao X, Hoareau R, Hockley BG, et al. Highlighting the Versatility of the Tracerlab Synthesis Modules. Part 1: Fully Automated Production of [<sup>18</sup>F]Labelled Radiopharmaceuticals using a Tracerlab FX<sub>FN</sub>. *J Labelled Comp Radiopharm.* 2011 5 30;54(6):292–307. [PubMed: 21769163]
19. Minoshima S, Koeppe RA, Fessler JA, et al. Integrated and automated data analysis method for neuronal activation studying using O<sup>15</sup> water PET In: Uemura K, Lassen NA, Jones T, Kanno I, editors. *Quantification of brain function to tracer kinetics and image analysis in brain PET.* Tokyo: Excerpta Medica; 1993 p. 409–18.
20. Aghourian M, Legault-Denis C, Soucy JP, et al. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [<sup>18</sup>F]-FEOBV. *Molecular psychiatry.* 2017 9 12;22(11):1531–8. [PubMed: 28894304]
21. Nejad-Davarani S, Koeppe RA, Albin RL, Frey KA, Muller M, Bohnen NI. Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [(18)F]-FEOBV. *Molecular psychiatry.* 2018 8 6.
22. Gilman S, Koeppe RA, Nan B, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. *Neurology.* 2010 5 4;74(18):1416–23. [PubMed: 20439843]
23. Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant signals in images of cerebral activation. *Human brain mapping.* 1996;4(1):58–73. [PubMed: 20408186]
24. Karachi C, Grabli D, Bernard FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. *J Clin Invest.* 2010 8 2;120(8):2745–54. [PubMed: 20628197]
25. Muller ML, Albin RL, Kotagal V, et al. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. *Brain: a journal of neurology.* 2013 11;136(Pt 11): 3282–9. [PubMed: 24056537]
26. Albin RL, Bohnen NI, Muller M, et al. Regional vesicular acetylcholine transporter distribution in human brain: A [(18) F]fluoroethoxybenzovesamicol positron emission tomography study. *J Comp Neurol.* 2018 9 26.

27. Parent M, Bedard MA, Aliaga A, et al. PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV). *Neuroimage*. 2012 8 1;62(1):555–61. [PubMed: 22555071]
28. Cyr M, Parent MJ, Mechawar N, et al. PET imaging with [(18)F]fluoroethoxybenzovesamicol ([18F]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat. *Nucl Med Biol*. 2014 1;41(1):96–101. [PubMed: 24267056]
29. Schmitz TW, Mur M, Aghourian M, Bedard MA, Spreng RN, Alzheimer's Disease Neuroimaging I. Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections. *Cell Rep*. 2018 7 3;24(1):38–46. [PubMed: 29972789]
30. Ballinger EC, Ananth M, Talmage DA, Role LW. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. *Neuron*. 2016 9 21;91(6):1199–218. [PubMed: 27657448]
31. Heckers S, Geula C, Mesulam M. Cholinergic innervation of the human thalamus: Dual origin and differential nuclear distribution. *J Comp Neurol*. 1992;325:68–82. [PubMed: 1282919]
32. Bohnen NI, Muller MLTM, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. *Journal of Cerebral Blood Flow and Metabolism*. 2012 8;32(8):1609–17. [PubMed: 22569194]
33. Halassa MM, Kastner S. Thalamic functions in distributed cognitive control. *Nature neuroscience*. 2017 12;20(12):1669–79. [PubMed: 29184210]
34. Vossel S, Geng JJ, Fink GR. Dorsal and ventral attention systems: distinct neural circuits but collaborative roles. *Neuroscientist*. 2014 4;20(2):150–9. [PubMed: 23835449]
35. Ebersbach G, Trottenberg T, Hattig H, Schelosky L, Schrag A, Poewe W. Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. *Brain: a journal of neurology*. 1996 2;119 (Pt 1):79–87. [PubMed: 8624696]
36. Wright WG, Gurfinkel V, King L, Horak F. Parkinson's disease shows perceptuomotor asymmetry unrelated to motor symptoms. *Neurosci Lett*. 2007 4 24;417(1):10–5. [PubMed: 17321682]
37. Sarter M, Albin RL, Kucinski A, Lustig C. Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. *Exp Neurol*. 2014 5 5;257C:120–9.
38. Snijders AH, Leunissen I, Bakker M, et al. Gait-related cerebral alterations in patients with Parkinson's disease with freezing of gait. *Brain: a journal of neurology*. 2011 1;134(Pt 1):59–72. [PubMed: 21126990]
39. Snijders AH, Takakusaki K, Debu B, et al. Physiology of freezing of gait. *Ann Neurol*. 2016 11;80(5):644–59. [PubMed: 27649270]
40. Bartels AL, Leenders KL. Brain imaging in patients with freezing of gait. *Movement disorders: official journal of the Movement Disorder Society*. 2008;23 Suppl 2:S461–7. [PubMed: 18668627]
41. Tessitore A, Amboni M, Esposito F, et al. Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. *Parkinsonism Relat Disord*. 2012 7;18(6):781–7. [PubMed: 22510204]
42. Shine JM, Matar E, Ward PB, et al. Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson's disease. *Brain: a journal of neurology*. 2013 3 12;136(Pt 4):1204–15. [PubMed: 23485851]
43. Fling BW, Cohen RG, Mancini M, Nutt JG, Fair DA, Horak FB. Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. *Brain: a journal of neurology*. 2013 8;136(Pt 8):2405–18. [PubMed: 23824487]
44. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annu Rev Neurosci*. 1986;9:357–81. [PubMed: 3085570]
45. Bradfield LA, Bertran-Gonzalez J, Chieng B, Balleine BW. The thalamostriatal pathway and cholinergic control of goal-directed action: interlacing new with existing learning in the striatum. *Neuron*. 2013 7 10;79(1):153–66. [PubMed: 23770257]
46. Gilat M, Ehgoetz Martens KA, Miranda-Dominguez O, et al. Dysfunctional Limbic Circuitry Underlying Freezing of Gait in Parkinson's Disease. *Neuroscience*. 2018 3 15;374:119–32. [PubMed: 29408498]

47. Martens KAE, Hall JM, Gilat M, Georgiades MJ, Walton CC, Lewis SJG. Anxiety is associated with freezing of gait and attentional set-shifting in Parkinson's disease: A new perspective for early intervention. *Gait & posture*. 2016 9;49:431–6. [PubMed: 27513741]
48. Videnovic A, Marlin C, Alibiglou L, Planetta PJ, Vaillancourt DE, Mackinnon CD. Increased REM sleep without atonia in Parkinson disease with freezing of gait. *Neurology*. 2013 9 17;81(12):1030–5. [PubMed: 23946301]
49. Kotagal V, Albin RL, Muller ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. *Ann Neurol*. 2012 4;71(4):560–8. [PubMed: 22522445]
50. Lord S, Galna B, Yarnall AJ, et al. Natural history of falls in an incident cohort of Parkinson's disease: early evolution, risk and protective features. *Journal of neurology*. 2017 11;264(11):2268–76. [PubMed: 28948348]




**Figure 1.** Main voxel-based SPM analysis comparing the total group of PD fallers *versus* non-fallers. Significant FEOBV binding reductions were found in the total group of PD fallers *versus* non-fallers in the dorsomedial thalamus (right greater than left), right LGN, right pulvinar, right head of the caudate nucleus, pre-frontal, right temporopolar, right more than left insula, superior vermis and bilateral superior cerebellar peduncle regions. Additional FEOBV binding reductions were present in the anterior cingulate cortex.




**Figure 2.** Main voxel-based SPM analysis comparing the PD freezers to the non-freezers demonstrated significant VAcHT binding reductions in the left hippocampal region, bilateral prefrontal and bilateral anterior cinguli. Additional reductions were seen in the striatum, including right more than left caudate and accumbens nuclei and putamina, bilateral limbic archicortex, bilateral gyri recti, right LGN, and right mid-cingulate cortex regions.





**Figure 3.**  
*Post hoc exploratory voxel-based SPM analysis comparing the subset of PD fallers without FoG to PD non-fallers also without FoG. There were more isolated reductions in the right LGN, right caudate nucleus, right premotor cortex, right frontal eye field, right temporopolar cortex, right lateral temporal, right posterior cingulum, right proximal lingual gyrus and bilateral prefrontal regions. Additional reductions were seen in the right more than left sensorimotor cortices.*



**Figure 4.**

*Post hoc exploratory* voxel-based SPM analysis comparing fallers with FoG to fallers without FoG showing more specific cholinergic transporter reductions in the left hippocampus, right temporal lobe, anterior cingulum, and cerebellum. Additional reductions were seen in the bilateral basal ganglia, limbic archicortex, right LGN and right insula.

**Table 1.**

Mean ( $\pm$ SD) values of demographic, clinical, cognitive data in the patients with PD without versus with falls (total n=94). Gender distribution is presented as proportions. Levels of statistical difference between groups are also presented.

	<b>PD non-fallers (n=59)</b>	<b>PD fallers (n=35)</b>	<b>Statistical significance</b>
Age	67.2 $\pm$ 7.3	68.9 $\pm$ 8.2	t=1.1; P=0.29
Gender (females/males)	16/43	6/29	Chi <sup>2</sup> =1.2; P=0.26
Duration of motor disease (years)	4.9 $\pm$ 3.5	8.0 $\pm$ 5.4	t=3.5; P=0.0008
Hoehn and Yahr stage	2.2 $\pm$ 0.6	2.8 $\pm$ 0.6	t=4.7; P<0.0001
Motor MDS-UPDRS	29.9 $\pm$ 10.5	40.7 $\pm$ 15.5	t=4.0; P=0.0001
Montreal Cognitive Assessment	27.0 $\pm$ 2.3	25.0 $\pm$ 4.2	t=2.4; P=0.02
History of acting out dreams (yes/no)	25/34	25/9 (n=34)	Chi <sup>2</sup> =0.4; P=0.004
LED (mg/d)	571.2 $\pm$ 333.9	797.6 $\pm$ 457.7	t =2.5; P=0.014

**Table 2.**

Mean ( $\pm$ SD) values of demographic, clinical, and cognitive data. Gender distribution is presented as proportions. Levels of statistical differences between groups are also presented.

	<b>PD without FoG (n=79)</b>	<b>PD with FoG (n=15)</b>	<b>Statistical significance</b>
Age	66.9 $\pm$ 6.8	73.1 $\pm$ 9.4	t=3.1; P=0.003
Gender (females/males)	20/59	2/13	Chi <sup>2</sup> =1.0; P=0.32
Duration of motor disease (years)	5.4 $\pm$ 4.5	9.1 $\pm$ 3.7	t =3.8; P=0.0003
Hoehn and Yahr stage	2.3 $\pm$ 0.5	3.2 $\pm$ 0.6	t=6.1; P<0.0001
Motor MDS-UPDRS	31.2 $\pm$ 12.6	48.5 $\pm$ 10.7	t =5.0; P<0.0001
Montreal Cognitive Assessment	26.8 $\pm$ 2.7	23.5 $\pm$ 4.7	t =3.2; P=0.0019
Acting out dreams (yes/no)	43/36	7/7 (n=14)	Chi <sup>2</sup> =0.4; P=0.004
LED (mg/d)	579.1 $\pm$ 366.3	1,057.9 $\pm$ 3,12.0	t =4.7; P<0.0001

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 3.**

Mean ( $\pm$ SD) values of bilaterally averaged [ $^{11}\text{C}$ ]FEOBV VAcHT distribution volume ratios in the patients with PD without versus with falls. Levels of statistical differences between groups are also presented (values with an asterisk remain significant after correction for Holm-Bonferroni multiple testing).

	<b>PD non-fallers (n = 59)</b>	<b>PD fallers (n = 35)</b>	<b>Statistical significance</b>
Brainstem	1.31 $\pm$ 0.09	1.26 $\pm$ 0.13	$t=2.1$ ; P=0.042
Cerebellum	1.34 $\pm$ 0.22	1.26 $\pm$ 0.19	$t=1.5$ ; P=0.15
Thalamus	1.91 $\pm$ 0.18	1.80 $\pm$ 0.24	$t= 3.3$ ; P=0.0016*
Striatum	4.50 $\pm$ 0.54	4.33 $\pm$ 0.69	$t=1.5$ ; P=0.14
Limbic archicortex	1.89 $\pm$ 0.15	1.84 $\pm$ 0.18	$t=1.5$ ; P=0.15
Neocortex	1.05 $\pm$ 0.08	1.04 $\pm$ 0.08	$t= 0.9$ ; P=0.38

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 4.**

Mean ( $\pm$ SD) values of bilaterally averaged [ $^{11}\text{C}$ ]FEOBV VChT distribution volume ratios in the patients with PD without versus with FoG. Levels of statistical differences between groups are also presented (values with an asterisk remain significant after correction for Holm-Bonferroni multiple testing).

	<b>PD without FoG (n=79)</b>	<b>PD with FoG (n=15)</b>	<b>Statistical significance</b>
Brainstem	1.30 $\pm$ 0.10	1.24 $\pm$ 0.15	$t=1.6$ ; $P=0.12$
Cerebellum	1.32 $\pm$ 0.22	1.25 $\pm$ 0.18	$t=1.0$ ; $P=0.33$
Thalamus	1.89 $\pm$ 0.20	1.76 $\pm$ 0.21	$t=2.1$ ; $P=0.04$
Striatum	4.53 $\pm$ 0.56	3.98 $\pm$ 0.64	$t=3.3$ $P=0.0012^*$
Limbic archicortex	1.90 $\pm$ 0.15	1.76 $\pm$ 0.17	$t=3.0$ ; $P=0.004^*$
Neocortex	1.05 $\pm$ 0.08	1.04 $\pm$ 0.09	$t=0.5$ ; $P=0.6$